Posted by Michael Wonder on 30 May 2017
Heart failure drug Entresto will be available on Pharmaceutical Benefits Scheme
30 May 2017 - Heart failure hospitalisations cost Tasmania more than $78.5 million a year, according to a new study, released on Tuesday.
The state has been named one of Australia’s top 10 heart failure “hot spots”, with 13,100 people living with the condition and a further 1800 diagnosed each year.
The analysis was conducted by the Mary MacKillop Institute for Health Research at the Australian Catholic University.
It was funded by Novartis Pharmaceuticals, which supplies the heart failure drug, called Entresto.
